News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Mylan Inc. Pulls EU Application for Generic Taxotere
March 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Mylan (MYL.O) has withdrawn its application to market a generic version of Sanofi-Aventis's (SASY.PA) cancer drug in Europe, after adverse feedback from regulators.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
RSV
Kennedy Follows RSV Recommendations of ACIP Members He Fired
July 3, 2025
·
3 min read
·
Tristan Manalac
Accelerated approval
Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity
July 3, 2025
·
2 min read
·
Tristan Manalac
Women’s health
Biotech Leaders, Investors Ask FDA to Maintain Access to Mifepristone
July 3, 2025
·
2 min read
·
Tristan Manalac
Legal
Court Suspends Mass Layoffs at HHS, Rules Staff Cuts Likely Unlawful
July 2, 2025
·
2 min read
·
Tristan Manalac
